We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-7.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.41B
AUM Growth
-$143M
Cap. Flow
+$78.9M
Cap. Flow %
5.61%
Top 10 Hldgs %
48.2%
Holding
246
New
54
Increased
32
Reduced
53
Closed
52

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$38M
2
FOLD
Amicus Therapeutics
FOLD
+$22M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$21.2M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.7M
5
ANIP icon
ANI Pharmaceuticals
ANIP
+$15.6M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$25.1M
2
DXCM icon
DexCom
DXCM
+$15.7M
3
AERI
Aerie Pharmaceuticals
AERI
+$13.5M
4
ASRT
Assertio
ASRT
+$13.4M
5
CRBP icon
Corbus Pharmaceuticals
CRBP
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.84%
2 Miscellaneous 1.6%
3 Consumer Staples 0.43%
4 Consumer Discretionary 0.07%
5 Industrials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
51
Vertex Pharmaceuticals
VRTX
$130B
$6.3M 0.45%
85,509
-21,491
-20% -$1.75M
NEPT
52
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$6M 0.43%
4,657
-165
-3% -$252K
FWP
53
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$5.92M 0.42%
56,320
-1,462
-3% -$193K
XENE icon
54
Xenon Pharmaceuticals
XENE
$5.45B
$5.7M 0.41%
740,272
-22,528
-3% -$181K
JAZZ icon
55
Jazz Pharmaceuticals
JAZZ
$15.6B
$5.67M 0.4%
+52,000
New +$5.79M
AKBA icon
56
Akebia Therapeutics
AKBA
$250M
$5.59M 0.4%
537,256
-271,840
-34% -$2.34M
SNDA icon
57
Sonida Senior Living
SNDA
$1.91B
$5.22M 0.37%
21,345
-3,675
-15% -$870K
EVH icon
58
Evolent Health
EVH
$423M
$4.55M 0.32%
307,800
-120,484
-28% -$2.37M
BIO icon
59
Bio-Rad Laboratories Class A
BIO
$10.1B
$4.45M 0.32%
24,416
+14,416
+144% +$2.46M
ALNY icon
60
Alnylam Pharmaceuticals
ALNY
$31.9B
$4.44M 0.32%
+118,475
New +$4.96M
ABEO icon
61
Abeona Therapeutics
ABEO
$313M
$4.08M 0.29%
33,687
-19,755
-37% -$3.09M
PPHMP
62
DELISTED
Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible
PPHMP
$3.98M 0.28%
+200,000
New +$4.09M
NVTA
63
DELISTED
Invitae Corporation
NVTA
$3.97M 0.28%
+500,000
New +$3.74M
EYPT icon
64
EyePoint Inc
EYPT
$316M
$3.9M 0.28%
227,971
-27,272
-11% -$553K
ABEOW
65
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
$3.78M 0.27%
1,259,636
– –
AGRX
66
DELISTED
Agile Therapeutics
AGRX
$3.77M 0.27%
331
-179
-35% -$2.51M
OTLK icon
67
Outlook Therapeutics
OTLK
$164M
$3.76M 0.27%
7,806
– –
ADMA icon
68
ADMA Biologics
ADMA
$1.93B
$3.69M 0.26%
721,102
-13,691
-2% -$78.6K
COLL icon
69
Collegium Pharmaceutical
COLL
$711M
$3.06M 0.22%
+196,728
New +$3.27M
CELG
70
DELISTED
Celgene Corp
CELG
$3.01M 0.21%
+26,000
New +$2.9M
SGYP
71
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$2.99M 0.21%
490,300
+401,173
+450% +$2.1M
OCGN icon
72
Ocugen
OCGN
$337M
$2.97M 0.21%
29,630
– –
MYOV
73
DELISTED
Myovant Sciences Ltd.
MYOV
$2.81M 0.2%
+226,322
New +$2.62M
MGCD
74
DELISTED
MGC Diagnostics Corporation
MGCD
$2.6M 0.19%
329,733
– –
RARX
75
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$2.51M 0.18%
+165,000
New +$2.24M
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2016 Portfolio in Review

As of Q4 2016, Perceptive Advisors held 246 positions worth $1.41B, down 9.2% from $1.55B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $78.9M of net new capital in Q4 2016, opening 54 new positions and adding to 32 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 304,531 shares worth $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $25.1M trimmed.

  • Perceptive Advisors's largest Q4 2016 buy was Lakefront Biotherapeutics American Depositary Shares: 304,531 shares worth $20.6M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q4 2016, an estimated $38M increase.
  • Perceptive Advisors's biggest Q4 2016 reduction was Sarepta Therapeutics, cutting an estimated $25.1M.
  • Perceptive Advisors fully exited DexCom in Q4 2016, selling an estimated $15.7M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.41B portfolio in Q4 2016.
  • Perceptive Advisors opened 54 new positions and closed 52 in Q4 2016.
  • Perceptive Advisors's portfolio value fell 9.2% quarter-over-quarter to $1.41B.

Based on Perceptive Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.